Niagen Bioscience, Stock Current Asset
| NAGE Stock | 9.04 0.31 3.32% |
Fundamental analysis of Niagen Bioscience, allows traders to better anticipate movements in Niagen Bioscience,'s stock price by examining its financial health and performance throughout various phases of its business cycle.
The current year's Total Current Assets is expected to grow to about 67.3 M. The current year's Non Current Assets Total is expected to grow to about 4.4 M. Niagen | Current Asset | Build AI portfolio with Niagen Stock |
Niagen Bioscience, Company Current Asset Analysis
Niagen Bioscience,'s Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Niagen Current Asset Historical Pattern
Today, most investors in Niagen Bioscience, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Niagen Bioscience,'s growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Niagen Bioscience, current asset as a starting point in their analysis.
Niagen Bioscience, Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Niagen Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Niagen Bioscience, has a Current Asset of 0.0. This is 100.0% lower than that of the Life Sciences Tools & Services sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Niagen Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Niagen Bioscience,'s direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Niagen Bioscience, could also be used in its relative valuation, which is a method of valuing Niagen Bioscience, by comparing valuation metrics of similar companies.Niagen Bioscience, is currently under evaluation in current asset category among its peers.
Niagen Fundamentals
| Return On Equity | 0.33 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 743.63 M | ||||
| Shares Outstanding | 78.77 M | ||||
| Shares Owned By Insiders | 34.44 % | ||||
| Shares Owned By Institutions | 30.59 % | ||||
| Number Of Shares Shorted | 3.49 M | ||||
| Price To Book | 14.37 X | ||||
| Price To Sales | 7.75 X | ||||
| Revenue | 99.6 M | ||||
| Gross Profit | 67.46 M | ||||
| EBITDA | 9.21 M | ||||
| Net Income | 8.55 M | ||||
| Total Debt | 2.65 M | ||||
| Book Value Per Share | 0.70 X | ||||
| Cash Flow From Operations | 12.11 M | ||||
| Short Ratio | 3.92 X | ||||
| Earnings Per Share | 0.18 X | ||||
| Target Price | 11.4 | ||||
| Number Of Employees | 104 | ||||
| Beta | 1.95 | ||||
| Market Capitalization | 836.53 M | ||||
| Total Asset | 68.28 M | ||||
| Retained Earnings | (181.91 M) | ||||
| Working Capital | 46.15 M | ||||
| Net Asset | 68.28 M |
About Niagen Bioscience, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Niagen Bioscience,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Niagen Bioscience, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Niagen Bioscience, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Niagen Bioscience, is a strong investment it is important to analyze Niagen Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Niagen Bioscience,'s future performance. For an informed investment choice regarding Niagen Stock, refer to the following important reports:Check out Niagen Bioscience, Piotroski F Score and Niagen Bioscience, Altman Z Score analysis. For information on how to trade Niagen Stock refer to our How to Trade Niagen Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Niagen Bioscience,. If investors know Niagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Niagen Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.18 | Revenue Per Share | Quarterly Revenue Growth 0.376 | Return On Assets | Return On Equity |
The market value of Niagen Bioscience, is measured differently than its book value, which is the value of Niagen that is recorded on the company's balance sheet. Investors also form their own opinion of Niagen Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Niagen Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Niagen Bioscience,'s market value can be influenced by many factors that don't directly affect Niagen Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Niagen Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Niagen Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Niagen Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.